Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Alight, Inc. / Delaware | Director | Class A Common Stock | 17.8K | $147K | $8.23 | Jan 2, 2024 | Direct |
NGM BIOPHARMACEUTICALS INC | President and CFO | Common Stock | 76K | $102K | $1.34 | Mar 2, 2023 | Direct |
NGM BIOPHARMACEUTICALS INC | President and CFO | Stock Option (Right to Buy) | 200K | Mar 2, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ALIT | Alight, Inc. / Delaware | Jan 2, 2024 | 1 | $0 | 4 | Jan 3, 2024 | Director |
ALIT | Alight, Inc. / Delaware | Jan 1, 2024 | 0 | $0 | 3 | Jan 3, 2024 | Director |
NGM | NGM BIOPHARMACEUTICALS INC | Mar 2, 2023 | 3 | $0 | 4 | Mar 6, 2023 | President and CFO |
NGM | NGM BIOPHARMACEUTICALS INC | Jul 1, 2022 | 1 | $0 | 4 | Jul 1, 2022 | President and CFO |
NGM | NGM BIOPHARMACEUTICALS INC | Mar 3, 2022 | 1 | $0 | 4 | Mar 4, 2022 | Chief Financial Officer |